![A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation ( A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (](https://europepmc.org/articles/PMC6794565/bin/GH_15_S2_fig6.jpg)
A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (
![A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation ( A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (](https://europepmc.org/articles/PMC6794565/bin/GH_15_S2_fig1.jpg)
A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (
![Entyvio® superior to Humira® in first head-to-head biologic clinical study in ulcerative colitis - The Evidence Base Entyvio® superior to Humira® in first head-to-head biologic clinical study in ulcerative colitis - The Evidence Base](https://www.evidencebaseonline.com/wp-content/uploads/2020/07/4ee644f6-32eb-4b33-85e1-783c706ad6a8-5f07184761f8d-scaled.jpg)
Entyvio® superior to Humira® in first head-to-head biologic clinical study in ulcerative colitis - The Evidence Base
![Janssen Demonstrates Strong Commitment To Advancing Science Of Inflammatory Bowel Diseases With Robust Selection Of Data Presentations At 14th Congress Of ECCO Janssen Demonstrates Strong Commitment To Advancing Science Of Inflammatory Bowel Diseases With Robust Selection Of Data Presentations At 14th Congress Of ECCO](https://mma.prnewswire.com/media/773032/Janssen_Pharmaceutical_Companies_of_Johnson_and_Johnson_Logo.jpg?p=twitter)
Janssen Demonstrates Strong Commitment To Advancing Science Of Inflammatory Bowel Diseases With Robust Selection Of Data Presentations At 14th Congress Of ECCO
![A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation ( A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (](https://europepmc.org/articles/PMC6794565/bin/GH_15_S2_fig3.jpg)
A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (
![Defining the Future of Inflammatory Bowel Disease Care: The Pivotal Role of Personalised Treatment - European Medical Journal Defining the Future of Inflammatory Bowel Disease Care: The Pivotal Role of Personalised Treatment - European Medical Journal](https://www.emjreviews.com/wp-content/uploads/2019/11/Hexal-Cover-Image-Supp.jpg)